Design and Analysis of Phase I Clinical Trials

Recommendations

The treatment versus experimentation dilemma in dose finding studies
A new look at evaluating MTD designs in cancer research
Bayesian optimal designs for phase I clinical trials
Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
An assessment of up- and down designs and associated estimators in phase I trials

Cited in

(only showing first 100 items - show all)

Unifying CRM and EWOC designs for phase I cancer clinical trials
Optimal Bayesian-feasible dose escalation for cancer phase I trials
Operating characteristics of the standard phase I clinical trial design.
Methodology and application of adaptive and sequential approaches in contemporary clinical trials
Number of patients per cohort and sample size considerations using dose escalation with overdose control
Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
Optimal designs for dose-escalation trials and individual allocations in cohorts
Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
An application of reinforced urn processes to determining maximum tolerated dose
A new look at evaluating MTD designs in cancer research
A semi-Markov model for patient progression through clinical trials
Adaptive clinical trial designs for phase I cancer studies
Group up-and-down designs for dose-finding
Theoretical study of the continual reassessment method
A conversation with Nancy Flournoy
A note on continual reassessment method
Continual reassessment method for partial ordering
Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials
A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
A simple technique to evaluate model sensitivity in the continual reassessment method
Dose-finding with two agents in phase I oncology trials
Bayesian optimal designs for phase I clinical trials
A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Designs for Single- or Multiple-Agent Phase I Trials
An assessment of up- and down designs and associated estimators in phase I trials
Analyzing longitudinal count data from adaptive clinical trials: a weighted generalized quasi-likelihood approach
Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
A sequential design for maximizing the probability of a favourable response
Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach
scientific article; zbMATH DE number 590042 (Why is no real title available?)
Sequential method of estimating the LD₅₀ using a modified up-and-down rule
Design issues for generalized linear models: a review
Designs foe phase i cancer clinical trials with differentiation of graded toxicity
The role of minimal sets in dose finding studies
Motivating sample sizes in adaptive phase I trials via Bayesian posterior credible intervals
Likelihood‐Based Experimental Design for Estimation of Ed 50
SEQUENTIAL METHODS IN CLINICAL TRIALS*
On the consistency of the continual reassessment method with multiple toxicity constraints
On multi-armed bandit designs for dose-finding trials
Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
A new design of the continual reassessment method
Sequential designs for ordinal phase I clinical trials
The adaptive accelerated biased coin design for phase I clinical trials
scientific article; zbMATH DE number 6428891 (Why is no real title available?)
A method based on isotonic regression estimation for identifying the maximum tolerated dose
The treatment versus experimentation dilemma in dose finding studies
Design and Analysis of Clinical Trials
The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses
Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
A Parallel Phase I/II Clinical Trial Design for Combination Therapies
Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
Retrospective Analysis of Sequential Dose‐Finding Designs
PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
Performance Measures in Dose‐Finding Experiments
A continual reassessment method without undue risk of toxicity
A modified Huber loss function for continual reassessment methods in clinical trials
Bayesian phase I/II adaptively randomized oncology trials with combined drugs
Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
A simulation-free approach to assessing the performance of the continual reassessment method
Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
Comparative review of novel model-assisted designs for phase I/II clinical trials
A nonparametric Bayesian method for dose finding in drug combinations cancer trials
A novel approach for propensity score matching and stratification for multiple treatments: application to an electronic health record-derived study
A machine learning compatible method for ordinal propensity score stratification and matching
A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
Early completion of phase I cancer clinical trials with Bayesian optimal interval design
Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
Dose finding studies for therapies with late-onset toxicities: a comparison study of designs
Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
Applying the partial order continual reassessment method to high-dimensional treatment combinations
Patient retreat in dose escalation for phase I clinical trials with rare diseases
Bayesian optimization for personalized dose-finding trials with combination therapies
The locally active-controlled optimal design: applications in oncology clinical studies
Causal inference in early phase clinical trials: variance decomposition and order of patient inclusion
Bridging continual reassessment method for phase I clinical trials in different ethnic populations
A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data
Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designs
UNITED: a unified transparent and efficient phase I/II trial design for dose optimization accounting for ordinal graded, continuous and mixed toxicity and efficacy endpoints
Competing designs for drug combination in phase I dose-finding clinical trials
Phase I/II adaptive design for drug combination oncology trials
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials
Adaptive dose modification for phase I clinical trials
Escalation with overdose control for phase I drug-combination trials
The rapid enrollment design for phase I clinical trials
PoD-BIN: a probability of decision Bayesian interval design for time-to-event dose-finding trials with multiple toxicity grades
Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities
Adaptive prior variance calibration in the Bayesian continual reassessment method
Two-stage dose finding for cytostatic agents in phase I oncology trials
STEIN: a simple toxicity and efficacy interval design for seamless phase I/II clinical trials

This page was built for publication: Design and Analysis of Phase I Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201544)